{"classes":[{"categories":[{"measurements":[{"comment":"Standard deviation was not estimable since only 1 participant was evaluable.","groupId":"OG000","spread":"NA","value":"-34.66"},{"comment":"Standard deviation was not estimable since only 1 participant was evaluable.","groupId":"OG001","spread":"NA","value":"287.52"},{"groupId":"OG002","spread":"283.61","value":"97.79"}]}],"title":"Day 1: post-dose (n=1, 1, 9)"},{"categories":[{"measurements":[{"comment":"Standard deviation was not estimable since only 1 participant was evaluable.","groupId":"OG000","spread":"NA","value":"562.48"},{"comment":"Standard deviation was not estimable since only 1 participant was evaluable.","groupId":"OG001","spread":"NA","value":"170.83"},{"groupId":"OG002","spread":"128.97","value":"3.88"}]}],"title":"Day 8: pre-dose (n=1, 1, 9)"},{"categories":[{"measurements":[{"comment":"Standard deviation was not estimable since only 1 participant was evaluable.","groupId":"OG000","spread":"NA","value":"528.62"},{"comment":"Standard deviation was not estimable since only 1 participant was evaluable.","groupId":"OG001","spread":"NA","value":"429.79"},{"groupId":"OG002","spread":"289.18","value":"143.57"}]}],"title":"Day 8: post-dose (n=1, 1, 9)"},{"categories":[{"measurements":[{"comment":"Standard deviation was not estimable since only 1 participant was evaluable.","groupId":"OG000","spread":"NA","value":"177.87"},{"groupId":"OG001","spread":"8.56","value":"-44.64"},{"groupId":"OG002","spread":"170.91","value":"119.23"}]}],"title":"Day 15: pre-dose (n=1, 2, 7)"},{"categories":[{"measurements":[{"comment":"Standard deviation was not estimable since only 1 participant was evaluable.","groupId":"OG000","spread":"NA","value":"-49.85"},{"groupId":"OG001","spread":"57.91","value":"-21.13"},{"groupId":"OG002","spread":"278.24","value":"138.45"}]}],"title":"Day 15: post-dose (n=1, 3, 7)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"9"}],"units":"Participants"}],"description":"CrkL is a protein, phosphorylation of which has been shown to correlate with CML cell growth; and conversely inhibition of their phosphorylation correlates with inhibition of tumor cell growth. Phosphorylation of CrkL was monitored in whole blood cells, as well as in the CD3+ (T cell), CD19+ (B cell) and CD34+ (blast cell) compartments by using FACS flow cytometry.\n\nNA = not estimable.","dispersionType":"Standard Deviation","groups":[{"description":"Single oral dose of bosutinib 400 mg on Day 1 and then bosutinib 400 mg orally once daily continuously from Day 3 up to Week 4. All participants who completed treatment in Part 1 were continued in CP2L-CML Part 2 of the study.","id":"OG000","title":"Bosutinib 400 mg (Part 1)"},{"description":"Single oral dose of bosutinib 500 mg on Day 1 and then bosutinib 500 mg orally once daily continuously from Day 3 up to Week 4. All participants who completed treatment in Part 1 were continued in CP2L-CML Part 2 of the study.","id":"OG001","title":"Bosutinib 500 mg (Part 1)"},{"description":"Single oral dose of bosutinib 600 mg on Day 1 and then bosutinib 600 mg orally once daily continuously from Day 3 up to Week 4. All participants who completed treatment in Part 1 were continued in CP2L-CML Part 2 of the study. Eleven participants who completed treatment in Part 1 were continued in CP2L-CML Part 2 of the study and 1 participant was continued in AP-CML Part 2 of the study.","id":"OG002","title":"Bosutinib 600 mg (Part 1)"}],"paramType":"MEAN","populationDescription":"Evaluable population included all enrolled participants who received at least 1 dose of study medication and had an adequate baseline efficacy assessment. 'N' signifies number of participants who were evaluable for this measure. n=number of participants evaluable for this measure at specified time points for each arm group respectively.","reportingStatus":"POSTED","timeFrame":"6 hours post-dose on Day 1, 0 (pre-dose), 6 hours post-dose on Day 8, 15","title":"Percent Change From Baseline in Phosphorylation Inhibition of Crk Like Protein (CrkL) at Day 1, 8 and 15 - Part 1","type":"SECONDARY","unitOfMeasure":"percent change"}